Literature DB >> 33656515

Immunodominant antibody germlines in COVID-19.

Emanuele Andreano1, Rino Rappuoli1,2.   

Abstract

The neutralizing antibody response to SARS-CoV-2 is dominated by antibodies deriving from germlines IGHV3-53/IGHV3-66, which are also associated with self-reacting antibodies. Could vaccines avoid the expansion of this immunodominant response, decrease the risk of autoimmunity, and still protect against emerging SARS-CoV-2 variants?
© 2021 Andreano and Rappuoli.

Entities:  

Year:  2021        PMID： 33656515     DOI： 10.1084/jem.20210281

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  10 in total

1.  Limited cross-variant immune response from SARS-CoV-2 Omicron BA.2 in naïve but not previously infected outpatients.

Authors:  Hye Kyung Lee; Ludwig Knabl; Mary Walter; Priscilla A Furth; Lothar Hennighausen
Journal:  medRxiv       Date:  2022-05-26

2.  Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron.

Authors:  Hye Kyung Lee; Jinyoung Go; Heungsup Sung; Seong Who Kim; Mary Walter; Ludwig Knabl; Priscilla A Furth; Lothar Hennighausen; Jin Won Huh
Journal:  iScience       Date:  2022-05-26

3.  Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential.

Authors:  Tracey E Mullen; Rashed Abdullah; Jacqueline Boucher; Anna Susi Brousseau; Narayan K Dasuri; Noah T Ditto; Andrew M Doucette; Chloe Emery; Justin Gabriel; Brendan Greamo; Ketan S Patil; Kelly Rothenberger; Justin Stolte; Colby A Souders
Journal:  Antib Ther       Date:  2021-08-28

4.  Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability.

Authors:  Deborah L Burnett; Katherine J L Jackson; David B Langley; Anupria Aggrawal; Alberto Ospina Stella; Matt D Johansen; Harikrishnan Balachandran; Helen Lenthall; Romain Rouet; Gregory Walker; Bernadette M Saunders; Mandeep Singh; Hui Li; Jake Y Henry; Jennifer Jackson; Alastair G Stewart; Franka Witthauer; Matthew A Spence; Nicole G Hansbro; Colin Jackson; Peter Schofield; Claire Milthorpe; Marianne Martinello; Sebastian R Schulz; Edith Roth; Anthony Kelleher; Sean Emery; Warwick J Britton; William D Rawlinson; Rudolfo Karl; Simon Schäfer; Thomas H Winkler; Robert Brink; Rowena A Bull; Philip M Hansbro; Hans-Martin Jäck; Stuart Turville; Daniel Christ; Christopher C Goodnow
Journal:  Immunity       Date:  2021-10-29       Impact factor: 43.474

5.  Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma.

Authors:  Matthias M Schneider; Marc Emmenegger; Catherine K Xu; Itzel Condado Morales; Georg Meisl; Priscilla Turelli; Chryssa Zografou; Manuela R Zimmermann; Beat M Frey; Sebastian Fiedler; Viola Denninger; Raphaël Pb Jacquat; Lidia Madrigal; Alison Ilsley; Vasilis Kosmoliaptsis; Heike Fiegler; Didier Trono; Tuomas Pj Knowles; Adriano Aguzzi
Journal:  Life Sci Alliance       Date:  2021-11-30

6.  mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron.

Authors:  Hye Kyung Lee; Ludwig Knabl; Juan I Moliva; Ludwig Knabl; Anne P Werner; Seyhan Boyoglu-Barnum; Sebastian Kapferer; Birgit Pateter; Mary Walter; Nancy J Sullivan; Priscilla A Furth; Lothar Hennighausen
Journal:  Cell Rep       Date:  2022-03-25       Impact factor: 9.995

7.  Engineering an Antibody V Gene-Selective Vaccine.

Authors:  Larance Ronsard; Ashraf S Yousif; Julianne Peabody; Vintus Okonkwo; Pascal Devant; Alemu Tekewe Mogus; Ralston M Barnes; Daniel Rohrer; Nils Lonberg; David Peabody; Bryce Chackerian; Daniel Lingwood
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

Review 8.  Vaccines Against COVID-19: A Review.

Authors:  Carlos U Torres-Estrella; María Del Rocío Reyes-Montes; Esperanza Duarte-Escalante; Mónica Sierra Martínez; María Guadalupe Frías-De-León; Gustavo Acosta-Altamirano
Journal:  Vaccines (Basel)       Date:  2022-03-10

Review 9.  Public Immunity: Evolutionary Spandrels for Pathway-Amplifying Protective Antibodies.

Authors:  Maya Sangesland; Daniel Lingwood
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

10.  The immunodominant antibody response to Zika virus NS1 protein is characterized by cross-reactivity to self.

Authors:  Cecilia B Cavazzoni; Vicente B T Bozza; Tostes C V Lucas; Luciana Conde; Bruno Maia; Luka Mesin; Ariën Schiepers; Jonatan Ersching; Romulo L S Neris; Jonas N Conde; Diego R Coelho; Tulio M Lima; Renata G F Alvim; Leda R Castilho; Heitor A de Paula Neto; Ronaldo Mohana-Borges; Iranaia Assunção-Miranda; Alberto Nobrega; Gabriel D Victora; Andre M Vale
Journal:  J Exp Med       Date:  2021-07-22       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.